Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

This study has been completed.
Sponsor:
Information provided by:
EMD Serono
ClinicalTrials.gov Identifier:
NCT00111839
First received: May 26, 2005
Last updated: October 23, 2013
Last verified: October 2013
  Purpose

This study is planned to answer questions about how the drug, matuzumab (EMD 72000), works and is part of an effort aimed to develop better treatment for advanced lung cancer by combining matuzumab, a monoclonal antibody, with a chemotherapy treatment, called pemetrexed. Pemetrexed is commercially available and has been approved for treatment of locally advanced or metastatic non-small cell lung cancer that could not be successfully treated with other chemotherapy.

The study aims to examine how non-small cell lung cancer (NSCLC) responds to matuzumab in combination with pemetrexed, as compared with giving pemetrexed alone. The study also aims to examine how safe and effective matuzumab is and for how long it stays in the body (pharmacokinetics). Matuzumab is an experimental treatment which is currently only available for research studies.


Condition Intervention Phase
Lung Cancer
Non Small Cell Lung Carcinoma
Drug: Pemetrexed
Drug: Matuzumab + Pemetrexed
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized, Phase II,Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine

Resource links provided by NLM:


Further study details as provided by EMD Serono:

Primary Outcome Measures:
  • Independent radiological response rate [ Time Frame: various timepoints measured ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: various timepoints measred ] [ Designated as safety issue: No ]
  • Time to tumor progression [ Time Frame: various timepoints measured ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: various timepoints measured ] [ Designated as safety issue: No ]
  • Safety and tolerability [ Time Frame: various timepoints measured ] [ Designated as safety issue: No ]
  • Quality of life [ Time Frame: various timepoints measured ] [ Designated as safety issue: No ]

Enrollment: 153
Study Start Date: May 2005
Study Completion Date: March 2009
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: Pemetrexed
pemetrexed 500mg per metre squared given i.v. (into the vein) every 3 weeks until progression of disease or unacceptable toxicity
Experimental: 2 Drug: Matuzumab + Pemetrexed
matuzumab 800mg given i.v. every week plus pemetrexed as in Group 1 until progression of disease or unacceptable toxicity
Experimental: 3 Drug: Matuzumab + Pemetrexed
matuzumab 1600mg given i.v. every 3 weeks plus pemetrexed as in Group 1 until progression of disease or unacceptable toxicity

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent provided prior to any screening procedure
  • Male or female,> 18 years of age
  • Histologically or cytologically confirmed diagnosis of non-small cell lung cancer
  • Demonstrated progressive disease on or after first-line chemotherapy for stage IIIB/IV disease. The first-line therapy must consist of platinum-based regimens in combination with taxanes,gemcitabine or vinorelbine.. Stage IIIB/IV patients must have measurable disease (tumor) without clinically significant pleural unless the pleural effusion can be effectively drained prior to admission into the study.
  • A chemotherapy-free interval of at least 3 weeks between the end of first-line chemotherapy and start of study treatment
  • At least 1 measurable lesion according to the modified WHO criteria
  • Archived tissue or cytologic sample available for the determination of EGFR expression
  • ECOG performance status 0-1
  • Life expectancy >12 weeks
  • Adequate baseline organ functions, defined as follows: *Serum creatinine ≤1.5 × upper limit of normal (ULN). In case of borderline values for serum creatinine, creatinine clearance must be ≥45 mL/min; *Total bilirubin <1.5 × ULN; *Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 × ULN (Subjects with liver metastases should have ALT/AST <5 × ULN.); *Absolute neutrophil count ≥1500/mm3; *Platelet count ≥100,000/mm3; *Hemoglobin level ≥10 g/dL11
  • If procreative potential (male or female), willingness to use effective contraceptive methods for the duration of treatment and continuing for 2 months after the last dose. Subjects of procreative potential are defined as any fertile male, or any female who has experienced menarche and who is not postmenopausal (defined as age-related amenorrhea ≥12 months) or who has not undergone successful surgical sterilization (hysterectomy or bilateral oophorectomy)

Exclusion Criteria:

  • Radiotherapy or major surgery within 30 days prior to the start of study treatment
  • Prior treatment with an EGFR-directed therapy or with EGFR signal transduction inhibitors
  • Prior treatment with pemetrexed
  • Pregnant (confirmed by β-HCG) or lactating female
  • Weight loss >10% within 12 weeks prior to the start of study treatment
  • Documented or symptomatic brain metastases or leptomeningeal disease
  • Myocardial infarction within 6 months prior to the start of study treatment, uncontrolled congestive heart failure, or any current New York Heart Association Grade III or IV cardiovascular disorder despite treatment
  • Presence of a ≥Grade 2 preexisting skin disorder (except for alopecia)
  • Previous diagnosis of autoimmune disease with significant organ involvement
  • Concurrent malignancies or invasive carcinomas diagnosed within the past 5 years, except for adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix
  • Any significant disease that, in the Investigator's opinion, should exclude the subject from the study
  • History of significant neurologic or psychiatric disorder (e.g., dementia, seizures, or bipolar disorder)
  • History of drug abuse within 6 months prior to the start of study treatment
  • Known conditions that require concurrent treatment with a nonpermitted drug
  • Presence of a contraindication to the study treatment(s) according to the current Investigator's Brochure (IB) for matuzumab and the labeling for pemetrexed
  • Known hypersensitivity to the study treatment or any of its components
  • Participation in another clinical study within 30 days prior to the start of study treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00111839

  Hide Study Locations
Locations
United States, Arizona
Arizona Clinical Research Center
Tucson, Arizona, United States, 85715
United States, Arkansas
University of Arkansas, Arkansas Cancer Research Center
Little Rock, Arkansas, United States, 72205
United States, California
University of Southern California/Norris Cancer Center
Los Angeles, California, United States, 90033
Sharp Memorial Hospital
San Diego, California, United States, 92123
United States, Florida
Holy Cross Hospital
fort Lauderdale, Florida, United States, 33308
Integrated Community Oncology Network
Jacksonville, Florida, United States, 32256
Cancer Center or Florida
Ocoee, Florida, United States, 34761
United States, Georgia
Peachtree Hematology and Oncology
Atlanta, Georgia, United States, 30309
Georgia Cancer Specialists
Tucker, Georgia, United States, 30084
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
University of Illinois
Chicago, Illinois, United States, 60612
Cancer Care Specialists of Central Illinois
Decatur, Illinois, United States, 62256
Cancer Institute of Alexian Brothers
Elk Grove Village, Illinois, United States, 60007
United States, Indiana
Hematology-Oncology of Indiana PC
Indianapolis, Indiana, United States, 46260
Indiana Oncology Hematology Consultants
Indianapolis, Indiana, United States, 46202
Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States, 46601
United States, Kansas
Kansas City Cancer Center
Overland Park, Kansas, United States, 66210
United States, Kentucky
Louisville Oncology
Louisville, Kentucky, United States, 40202
James Graham Brown Cancer Center
Louisville, Kentucky, United States, 40402
United States, Louisiana
Hematology-Oncology Clinic
Baton Rouge, Louisiana, United States, 70808
United States, Maryland
Frederick Memorial Hospital
Frederick, Maryland, United States, 21701
United States, Massachusetts
Tuffs-New England Medical Center
Boston, Massachusetts, United States, 20111
United States, Michigan
Henry Ford Health Systems
Detroit, Michigan, United States, 48202
West Michigan Regional Cancer and Blood Center
Free Soil, Michigan, United States, 49411
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
University of Missouri
Columbia, Missouri, United States, 65203
United States, Montana
Deaconess Billings Clinic
Billings, Montana, United States, 59101
United States, Nebraska
Nebraska Hematology-Oncology, PC
Lincoln, Nebraska, United States, 68506
United States, New Hampshire
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
United States, New York
New York Oncology
Albany, New York, United States, 12208
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States, 27599
Presbyterian Hospital Cancer Center
Charlotte, North Carolina, United States, 28204
United States, Ohio
The Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Dayton Oncology and Hematology
Kettering, Ohio, United States, 45409
United States, Oregon
Providence Portland Medical Center
Portland, Oregon, United States, 97213
United States, Pennsylvania
Hematology & Oncology Associates of NEPA
Dunmore, Pennsylvania, United States, 19107
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107
United States, Texas
Mary Crowley Research Center
Dallas, Texas, United States, 75246
Tyler Cancer Center
Tyler, Texas, United States, 75702
United States, Washington
Rainer Oncology Professional Services
Puyallup, Washington, United States, 98372
Cancer Care Northwest
Spokane, Washington, United States, 99218
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792
Austria
Research Site
Linz, Austria
Research Site
Salzburg, Austria
Research Site
Wels, Austria
Research Site
Wien, Austria
Germany
Research Site
Essen, Germany
Research Site
Freiburg, Germany
Research Site
Gauting, Germany
Research Site
Grosshansdorf, Germany
Research Site
Göttingen, Germany
Research Site
Halle /Saale, Germany
Research Site
Hamburg, Germany
Research Site
Heidelberg, Germany
Research Site
Köln, Germany
Research Site
Mainz, Germany
Research Site
München, Germany
Research Site
Recklinghausen, Germany
Sponsors and Collaborators
EMD Serono
Investigators
Principal Investigator: Joan Schiller, MD University of Texas
Principal Investigator: Mark Socinski, MD University of North Carolina, Chapel Hill
  More Information

No publications provided

Responsible Party: Claire Beadman, Merck KGaA
ClinicalTrials.gov Identifier: NCT00111839     History of Changes
Other Study ID Numbers: EMD 72000-031
Study First Received: May 26, 2005
Last Updated: October 23, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by EMD Serono:
Lung cancer

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Pemetrexed
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Antimetabolites, Antineoplastic
Antimetabolites

ClinicalTrials.gov processed this record on July 26, 2014